Abstract
The elevation of AKT activity in many aggressive tumors, and AKT signaling is frequently compromised in various cancers. The range of AKT inhibitors' therapeutic effects extends beyond cancer management. AKT inhibitors may potentially be used to treat cancer. The study aims to find a potent drug compound from D. kaki polyphenols that could serve as an AKT1 inhibitor. In silico study using Molecular operating environment (MOE) software was employed to find the therapeutic potential of phytochemicals from D. kaki against AKT1 via molecular docking and drug-like properties. Results of the study revealed that acarbose (compound 1) has the highest docking score of -7.4615 with receptor protein 6CCY, followed by quercetin 3-O-glucoside (compound 2) with a docking score of -6.86404133 measured in terms of kcal/mol. Pocket residues involved in protein-ligand interaction was GLU234, GLU278, ASP292, ASN79, LYS276, LYS189, PHE161, HIS194, LYS179, ASP291, LYS158, GLU278. Thus, bioactive compounds from D. kaki may be a potentially novel anticancer agent by inhibiting AKT1.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
